MADRID — Patients with lupus nephritis who were treated with a voclosporin-based combination therapy met all primary and secondary endpoints, including durable complete remission, according to findings presented at the EULAR Annual Congress.“Voclosporin [Aurinia Pharmaceuticals] combined with [mycophenolate mofetil] MMF and steroids leads to increased rates and duration of complete response in patients with active lupus nephritis,” Vladimir Dobronravov, MD, of Pavlov First St. Petersburg State Medical University in St. Petersburg, Russian Federation, said. “AURA-LV is the first global study to meet the primary endpoint and all secondary endpoints in patients with active lupus nephritis. A multi-targeted approach allowed for clinical response using a steroid-reduced protocol with an appropriate safety profile.”

More From BioPortfolio on "Voclosporin therapy reached study endpoints at 48 weeks for patients with lupus nephritis"

Relevant Topics

LupusLupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening.
There are several types of lupus. The main types are:
discoid lupus erythematosus
drug-induced lu...